Replimune surges 85.7% following FDA path-forward agreement on melanoma drug RP1
#Replimune shares surged 85.7% to close at $8.69 on Friday following an announcement that the company and FDA have aligned on a path forward for resubmission of its Biologics License Application.
#The agreement allows the company to resubmit its application for RP1 in combination with Nivolumab to treat advanced melanoma in the coming days.
#This follows two prior FDA rejections over study design concerns, with the company now positioned to resubmit after regulatory discussions.
Dell surges 32.8% on Q1 earnings beat and record AI server revenue growth
#Dell Technologies shares jumped 32.8% to close at $420.91 on Friday following a blowout first-quarter earnings report.
#The computing giant raised its full-year outlook as first-quarter AI-optimized server revenue surged 757%, driven by booming demand for artificial intelligence infrastructure.
#Trading volume reached 38.18 million shares, representing more than five times its recent daily average.
Okta jumps 30.1% on Q1 earnings beat and raised outlook
#Okta shares jumped 30.1% to close at $123.27 on Friday after reporting first-quarter results that beat Wall Street's sales and earnings estimates.
#The identity management company raised its full-year guidance, driven by accelerating subscription growth and emerging AI-driven identity product demand.
#Trading volume reached 17.18 million shares, which is 5.5 times its 20-day average of 3.13 million shares.